Tecan Group AG/€TECN
1D1W1MYTD1Y5YMAX
Capital at risk
About Tecan Group AG
Tecan Group AG is a Swiss company specializing in laboratory instruments and solutions within the life sciences sector. The company offers a range of automated workflow and instrumentation solutions for laboratories involved in diagnostics, bio-pharmaceuticals, and forensics. Founded in 1980 and headquartered in Männedorf, Switzerland, Tecan operates globally, serving clients across various continents. The company's strategic positioning lies in its emphasis on automation and high-throughput systems, which cater to the growing demand for efficiency in laboratory settings. Tecan's products are characterized by their precision and adaptability, allowing for integration into diverse laboratory environments.
- Ticker
- €TECN
- Sector
- Health
- Primary listing
- XGAT
- Employees
- 3,000
- Headquarters
- Männedorf, Switzerland
- Website
- www.tecan.com
Tecan Group AG Metrics
BasicAdvanced
€2.9B
-
-€9.83
1.08
€3.27
0.71%
Price and volume
Market cap
€2.9B
Beta
1.08
52-week high
€223.20
52-week low
€121.40
Average daily volume
58K
Dividend rate
€3.27
Financial strength
Current ratio
2.316
Quick ratio
1.495
Long term debt to equity
0.182
Total debt to equity
0.192
Interest coverage (TTM)
15.09%
Profitability
EBITDA (TTM)
77.342
Gross margin (TTM)
34.06%
Net profit margin (TTM)
-13.36%
Operating margin (TTM)
4.55%
Effective tax rate (TTM)
-7.05%
Revenue per employee (TTM)
€306,570
Management effectiveness
Return on assets (TTM)
1.38%
Return on equity (TTM)
-9.69%
Valuation
Price to revenue (TTM)
3.135
Price to book
2.41
Price to tangible book (TTM)
9.36
Price to free cash flow (TTM)
65.994
Free cash flow yield (TTM)
1.52%
Free cash flow per share (TTM)
3.496
Dividend yield (TTM)
1.42%
Forward dividend yield
0.71%
Growth
Revenue change (TTM)
-3.98%
Earnings per share change (TTM)
-287.88%
3-year revenue growth (CAGR)
-7.55%
10-year revenue growth (CAGR)
6.23%
3-year earnings per share growth (CAGR)
3.12%
10-year earnings per share growth (CAGR)
7.01%
3-year dividend per share growth (CAGR)
1.14%
10-year dividend per share growth (CAGR)
5.54%
Bulls say / Bears say
Solid H1 2026 sales growth of 3.4% in local currencies outpaced broader market trends, underscoring Tecan’s resilient top-line performance (FT.com).
Order entry rose 3.0% in local currencies in H1 2026, with a book-to-bill ratio remaining above 1, indicating robust demand momentum and backlog strength (Tecan Group AG).
Tecan launched direct sales and specialist lab automation services in India in May 2026, strengthening its presence in a high-growth life sciences market (Tecan Group AG).
Adjusted EBITDA margin of 15.1% in H1 2026 remained well below the medium-term target of 20%, pressured by combined foreign exchange and tariff headwinds totalling 170 basis points (Tecan Group AG).
Gross margin contracted to 33.9% in H1 2026 from 36.2% a year earlier, reflecting persistent cost inflation, FX volatility and tariff impacts (Investing.com).
Supply-chain disruptions in the Cavro OEM components business prevented shipment of planned backlog in H1 2026, exposing execution risks in a key segment (Investing.com).
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2026.
Upcoming events
No upcoming events
Funds containing Tecan Group AG
Fund name | Fund size | €TECN weighting |
|---|---|---|
WisdomTree Global Quality Dividend Growth£GGRG | £1.9B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.